BioSyent (RX) Stock Price, News & Analysis

Company Overview

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.

Key Stats

• Today's Range: C$13.83 to C$14.18
• 50-Day Range: C$13.70 to C$15.70
• 52-Week Range: C$10.65 to C$15.80
• Volume: 7,302 shs
• Average Volume: 5,587 shs
• Market Capitalization: C$159.56 million
• P/E Ratio: 17.79
• Dividend Yield: 1.47%
• Price Target: N/A
• Consensus Rating: Strong Buy

BioSyent Stock Analysis - MarketRank™

BioSyent scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.0 / 5
• Analyst Rating: Strong Buy

Amount of Analyst Coverage

BioSyent has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BioSyent is 17.79, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.10.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioSyent is 17.79, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.90.

Price to Book Value per Share Ratio

BioSyent has a P/B Ratio of 3.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for RX.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

BioSyent pays a meaningful dividend of 1.61%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

BioSyent does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of BioSyent is 26.15%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: N/A

News Sentiment

BioSyent has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for BioSyent this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for RX on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BioSyent insiders have sold more of their company's stock than they have bought. Specifically, they have bought C$0.00 in company stock and sold C$29,875.00 in company stock.

Percentage Held by Insiders

33.65% of the stock of BioSyent is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

12.70% of the stock of BioSyent is held by institutions.

Company Calendar

• Last Earnings: 5/25/2017
• Today: 5/26/2026

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: CVE:RX
• CIK: N/A
• Web: www.biosyent.com
• Phone: +1-905-2060013
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C$0.78
• Trailing P/E Ratio: 17.79
• Forward P/E Ratio: 20.09
• P/E Growth: N/A
• Net Income: C$7.02 million
• Net Margins: 19.65%
• Pretax Margin: N/A
• Return on Equity: 22.05%
• Return on Assets: 12.86%

Debt

• Debt-to-Equity Ratio: 11.66
• Current Ratio: 1.89
• Quick Ratio: 6.91

Sales & Book Value

• Annual Sales: C$45.98 million
• Price / Sales: 3.47
• Cash Flow: C$4.54 per share
• Price / Cash Flow: 3.07
• Book Value: C$3.97 per share
• Price / Book: 3.51

Miscellaneous

• Outstanding Shares: 11,438,000
• Free Float: N/A
• Market Cap: C$159.56 million
• Optionable: Not Optionable
• Beta: 1.02